Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex Pharmaceuticals (Nasdaq: VRTX) will take part in two upcoming investor conferences in June 2024. CEO Dr. Reshma Kewalramani will present at the William Blair 44th Annual Growth Stock Conference on June 4 at 4:00 p.m. CT. Executives Charles Wagner and Dr. David Altshuler will join a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11 at 11:20 a.m. ET. Both events will be webcast live on the Vertex website, with replays available afterward.
Vertex Pharmaceuticals (Nasdaq: VRTX) has elected Jennifer Schneider, M.D., M.S., to its Board of Directors as an independent director. Dr. Schneider brings over 20 years of expertise in the healthcare sector. She co-founded and leads Homeward Health, targeting healthcare delivery for rural Americans. Previously, she was President and Chief Medical Officer of Livongo Health, where she steered the company through a record-breaking IPO and a major merger with Teladoc Health. Dr. Schneider's background also includes roles at Castlight Health and research at Stanford University. Her addition brings Vertex's board to 11 members, 45% of whom are women. Dr. Schneider's experience is poised to aid Vertex's growth and innovation, particularly in cystic fibrosis, sickle cell disease, and beta thalassemia.
Alpine Immune Sciences reported its financial results for the first quarter of 2024, with a cash position of $362.4 million. Vertex Pharmaceuticals will acquire Alpine for $65 per share, expected to close in Q2 2024. Collaboration revenue decreased to $7.0 million, with an increase in research and development expenses to $22.5 million. Net loss for Q1 2024 was $17.9 million.
Vertex Pharmaceuticals reported a 13% increase in product revenue to $2.69 billion in Q1 2024 compared to Q1 2023. They submitted filings for vanzacaftor triple in CF to FDA and EMA, initiated NDA submission for suzetrigine in acute pain, and agreed to acquire Alpine Immune Sciences. Vertex's full year 2024 guidance includes product revenue of $10.55 to $10.75 billion.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.